Premium
Nonseminomatous germ cell cancer of the testis. Reducing treatment‐related morbidity in patients with disseminated disease
Author(s) -
Paschal Barton R.,
Muss Hyman B.,
Richards Frederick,
Cooper M. Robert,
White Douglas R.,
Jackson Don V.,
Stuart John J.,
Spurr Charles L.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19821101)50:9<1742::aid-cncr2820500916>3.0.co;2-u
Subject(s) - medicine , radiation therapy , chemotherapy , disease , regimen , cancer , seminoma , surgery , testicular cancer , germ cell tumors , oncology
Fourteen previously untreated patients with metastatic nonseminomatous germ cell cancer of the testis (NSGC) were treated with a modified VAB‐4 regimen which was designed to reduce treatment‐related morbidity. Nine of 10 patients with minimal disease and the only patient with advanced pulmonary disease achieved a complete response (CR) with chemotherapy alone. Two of three partial responders with advanced abdominal disease were converted to CR status with radiotherapy and/or surgery. None of the 12 CRs have relapsed (median duration of follow‐up, 28+ months). We observed no granulocytopenic fever or permanent renal insufficiency. These results indicate that NSGC patients with a low tumor burden can be spared substantial toxicity without adversely affecting complete response rates. Cancer 50:1742‐1745, 1982.